Erasmus University Medical Center, Department of Pediatrics, division of Pediatric Cardiology, Rotterdam, the Netherlands; Erasmus University Medical Center, Department of Radiology, Rotterdam, the Netherlands; Netherlands Heart Institute, Utrecht, the Netherlands.
Erasmus University Medical Center, Department of Pediatrics, division of Pediatric Cardiology, Rotterdam, the Netherlands; Netherlands Heart Institute, Utrecht, the Netherlands.
Int J Cardiol. 2022 Aug 15;361:31-37. doi: 10.1016/j.ijcard.2022.04.065. Epub 2022 Apr 26.
To determine the potential prognostic value and clinical correlations of blood biomarkers in a cohort of patients with Tetralogy of Fallot (TOF).
In the setting of multicenter prospective research studies TOF patients underwent blood sampling, cardiopulmonary exercise testing and low-dose dobutamine stress cardiac magnetic resonance (CMR) imaging. In the blood sample NT-proBNP, GDF-15, Galectin-3, ST-2, DLK-1, FABP4, IGFBP-1, IGFBP-7, MMP-2, and vWF were assessed. During subsequent follow-up, patients were evaluated for reaching the study endpoint (cardiac death, arrhythmia-related hospitalization or cardioversion/ablation, VO max ≤65% of predicted). Regression analysis was used to explore the correlation between blood biomarkers (corrected for age and gender) and other clinical parameters. The potential predictive value of blood biomarkers and events were assessed with Kaplan-Meier analysis and Cox proportional hazard analysis.
We included 137 Fallot patients, median age 19.2 (interquartile range: 14.6-25.7) years, median age at TOF-repair 0.9 (0.5-1.9) years. After a median follow-up of 8.7 (6.3-10.7) years, 20 (14.6%) patients reached the composite endpoint. In a multivariable cox-regression analysis corrected for age at study baseline, elevated IGFBP-7 and MMP-2 levels were associated with the composite endpoint. We also noted a correlation between DLK-1 and relative change in right ventricular end systolic volume during dobutamine stress CMR (β = -0.27, p = 0.010), a correlation between FABP4 and Max VO (β = -0.41, p ≤0.001 and between MMP-2 and tricuspid valve E/A ratio (β = -0.15, p = 0.037).
IGFBP-7, MMP-2 and DLK-1 levels are related to cardiac function and long-term outcome in TOF patients.
为了确定在法洛四联症(TOF)患者队列中血液生物标志物的潜在预后价值和临床相关性。
在多中心前瞻性研究中,TOF 患者接受了血液采样、心肺运动试验和低剂量多巴酚丁胺应激心脏磁共振(CMR)成像。在血液样本中,评估了 NT-proBNP、GDF-15、半乳糖凝集素-3、ST-2、DLK-1、FABP4、IGFBP-1、IGFBP-7、MMP-2 和 vWF。在随后的随访中,评估患者是否达到研究终点(心脏死亡、心律失常相关住院或电复律/消融、VO max ≤预测值的 65%)。回归分析用于探索血液生物标志物(校正年龄和性别)与其他临床参数之间的相关性。通过 Kaplan-Meier 分析和 Cox 比例风险分析评估血液生物标志物和事件的预测价值。
我们纳入了 137 例法洛四联症患者,中位年龄为 19.2 岁(四分位距:14.6-25.7 岁),TOF 修复时的中位年龄为 0.9 岁(0.5-1.9 岁)。在中位随访 8.7 年后(6.3-10.7 年),20 例(14.6%)患者达到了复合终点。在校正研究基线时年龄的多变量 Cox 回归分析中,IGFBP-7 和 MMP-2 水平升高与复合终点相关。我们还注意到 DLK-1 与多巴酚丁胺应激 CMR 期间右心室收缩末期容积的相对变化之间存在相关性(β=-0.27,p=0.010),FABP4 与 Max VO 之间存在相关性(β=-0.41,p≤0.001)和 MMP-2 与三尖瓣 E/A 比值之间存在相关性(β=-0.15,p=0.037)。
IGFBP-7、MMP-2 和 DLK-1 水平与 TOF 患者的心脏功能和长期预后相关。